Analysts Offer Predictions for Insulet Corp.’s Q3 2016 Earnings (PODD)
Insulet Corp. (NASDAQ:PODD) – Investment analysts at B. Riley issued their Q3 2016 earnings per share estimates for Insulet Corp. in a report issued on Tuesday. B. Riley analyst G. Chodaczek anticipates that the brokerage will post earnings of ($0.08) per share for the quarter. B. Riley currently has a “Neutral” rating and a $46.00 price target on the stock. B. Riley also issued estimates for Insulet Corp.’s Q4 2016 earnings at ($0.07) EPS, FY2016 earnings at ($0.41) EPS, Q1 2017 earnings at ($0.08) EPS, Q2 2017 earnings at ($0.04) EPS, Q3 2017 earnings at ($0.04) EPS, Q4 2017 earnings at $0.02 EPS and FY2017 earnings at ($0.14) EPS.
Insulet Corp. (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The company earned $87.30 million during the quarter, compared to the consensus estimate of $81.10 million. Insulet Corp. had a negative net margin of 17.68% and a negative return on equity of 137.88%. The company’s revenue for the quarter was up 44.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.30) earnings per share.
PODD has been the subject of several other research reports. Zacks Investment Research upgraded shares of Insulet Corp. from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Tuesday, July 5th. Canaccord Genuity reaffirmed a “hold” rating and issued a $36.00 price objective on shares of Insulet Corp. in a report on Friday, August 5th. Wedbush reaffirmed an “outperform” rating and issued a $44.00 price objective on shares of Insulet Corp. in a report on Wednesday, July 20th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $41.00 price objective on shares of Insulet Corp. in a report on Wednesday, July 20th. Finally, Jefferies Group raised their price objective on shares of Insulet Corp. from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $41.50.
Insulet Corp. (NASDAQ:PODD) opened at 39.53 on Thursday. Insulet Corp. has a one year low of $23.94 and a one year high of $45.60. The stock’s 50 day moving average is $42.92 and its 200 day moving average is $34.94. The firm’s market capitalization is $2.26 billion.
A number of institutional investors have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Insulet Corp. by 3.0% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,339 shares of the company’s stock worth $111,000 after buying an additional 98 shares during the last quarter. Walleye Trading LLC boosted its position in shares of Insulet Corp. by 226.3% in the second quarter. Walleye Trading LLC now owns 3,410 shares of the company’s stock worth $103,000 after buying an additional 6,110 shares during the last quarter. BOKF NA acquired a new position in shares of Insulet Corp. during the second quarter worth approximately $111,000. BNP Paribas Arbitrage SA boosted its position in shares of Insulet Corp. by 113.5% in the second quarter. BNP Paribas Arbitrage SA now owns 3,691 shares of the company’s stock worth $112,000 after buying an additional 1,962 shares during the last quarter. Finally, Amalgamated Bank acquired a new position in shares of Insulet Corp. during the second quarter worth approximately $261,000.
Insulet Corp. Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM).
Receive News & Stock Ratings for Insulet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corp. and related stocks with our FREE daily email newsletter.